Innocare Pharma Ltd. Class A · SSE:688428
Innocare Pharma Ltd. Class A — Investor Presentation (January 2023)
19 slides from Innocare Pharma Ltd. Class A's investor presentation, Jan 11, 2023
Slide 1: InnoCare Pharma (9969.HK, 688428.SH)
InnoCare Pharma (9969.HK, 688428.SH) January 11, 2023 1
Slide 2: Disclaimer
Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subs
Slide 3: Our Vision
Our Vision To Become a Global Biopharmaceutical Leader that Develops and Delivers Innovative Therapies for Patients Worldwide Oncology Autoimmune Our Therapeutic Focus 3
Slide 4: Transforming from Biotech to Biopharma
Transforming from Biotech to Biopharma Snapshot of Achievements in 2022 Q1-Q3 Rapidly Business Development Accelerated Commercialization Maturing Pipeline Progressing ■ Total revenue reached RMB 442mn, ■ 13 clinical assets in total ■ Out-licensing including RMB 400mn of Orelabrutinib ❑ Orelabrutinib
Slide 5: Commercialization Update
Commercialization Update Strong Sales Ramp-up with Orelabrutinib Robust Net Sales Growth1 Successful Commercialization Strategy ■ Net sales achieved RMB 400mn in 2022Q1-Q3 ■ Swift implementation of NRDL at local level ■ Experienced and effective in-house commercial team ■ Rapid coverage of hematolog
Slide 6: Product Pipeline – Liquid Cancer
Research & Development Product Pipeline – Liquid Cancer Dose Escalation Dose Expansion Pivotal Trial Drug Target Indication(s) Rights IND Enabling Filed Market PHIa PHIb PH2* PH2** PH3 NDA approved: 25 Dec 2020 CHN r/r CLL/SLL CHN, SG r/r MCL NDA approved: 25 Dec 2020 r/r MZL NDA accepted by NMPA in
Slide 7: Product Pipeline – Solid Tumor & Autoimmune Disease
Research & Development Product Pipeline – Solid Tumor & Autoimmune Disease Dose Escalation Dose expansion Pivotal Trial Drug Target Indication(s) Rights IND Enabling Filed Market PHIa PHIb PH2* PH2** PH3 Cholangiocarcinoma Urothelial cancer ICP-192/ pan-FGFR Gunagratinib Head & Neck pan-FGFR (Basket
Slide 8: Differentiated strategy to be the leader in Hematology
1 Major Program Update Differentiated strategy to be the leader in Hematology ICP-490 Small Molecule E3 Ligase ICP-B02 ICP-B05 ICP-248 Biologics Small Molecule Biologics CD3*CD20 BCL2 CCR8 ICP-490 Orelabrutinib Tafasitimab ICP-248 Small Molecule Small Molecule Small Molecule Biologics E3 Ligase BTK
Slide 9: Orelabrutinib (ICP-022): Comprehensive Coverage in Hematology
1 Major Program Update Orelabrutinib (ICP-022) : Comprehensive Coverage in Hematology ■ Orelabrutinib has been approved for r/r MCL in Singapore ■ r/r WM NDA was accepted and the site inspection was completed; r/r MZL NDA was included in priority review by CDE ■ 1L DLBCL - MCD registrational trial e
Slide 10: Differentiated strategy in DLBCL well defined
1 Major Program Update Differentiated strategy in DLBCL well defined ▪ MCD subtype DLBCL identified as a subgroup with potentially high sensitivity to BTKis ❑ MCD subgroup is predominantly enriched with B-cell receptor-dependent NF-κB activation which indicates this patient sub-group might respond w
Slide 11: Orelabrutinib: SLE Phase II Positive Results Lead to Further Development
2 Major Program Update Orelabrutinib (ICP-022) : SLE Phase II Positive Results Lead to Further Development SRI-4 Response Rate at 12 Weeks SLE Phase II Study Results1 ▪ SLE Responder Index (“SRI”)-4 response rates increased in a dose dependent manner ▪ Trends of reduction in proteinuria level and im
Slide 12: Tafasitamab: Potential Best Therapy for r/r DLBCL
3 Major Program Tafasitamab: Potential Best Therapy for r/r DLBCL Current Status and Further Development ■ Pivotal trial for r/r DLBCL is ongoing to support approval in mainland China ■ Approved for Urgent Clinical Use in the Hainan Province, 1st patients reached CR after 2 cycles treatment ■ Tafasi
Slide 13: TYK2 inhibitors: ICP-332 & ICP-488
4 Major Program Update TYK2 inhibitors: ICP-332 & ICP-488 ICP-332 (TYK-2, JH1) ■ Safe and well-tolerated, no significant 10 4 Phase I MAD Results decrease of platelet and hemoglobin Plasma concentration (ng/mL) 40 mg 10 3 80 mg (JAK2-related AE) observed in 160 mg Cav: 260 ng/mL (160 mg) Phase I stu
Slide 14: ICP-192: Promising Safety and Efficacy Seen in Phase II trials
5 Major Program Update ICP-192: Promising Safety and Efficacy Seen in Phase II trials ICP-192 (Gunagratinib, FGFR) ■ Finished dose-escalation ranging from 2 mg to 26 mg and no DLT observed ■ Safe and well-tolerated in patients with advanced solid tumors ■ 20 mg showed efficacy in cholangiocarcinoma
Slide 15: ICP-723: Favorable Clinical Results with Potential Best-in-Class Profile
6 Major Program Update ICP-723: Favorable Clinical Results with Potential Best-in-Class Profile NTRK Gene Fusion Mutation is an Oncogenic Driver for a ICP-723 (TRK) Variety of Cancer Types ■ 2nd generation TRKi overcomes acquired resistance to 1st generation TRKi ■ No DLTs observed in Phase I (1-16
Slide 16: Continuous Strong Flow of Early Stage Projects
7 Other Program Update Continuous Strong Flow of Early Stage Projects Entered Phase I ■ ICP-B02 / CM355 (CD3 x CD20) ❑ First patient enrolled in Feb 2022 and Phase I trial ongoing in China ■ ICP-189 (SHP2) ❑ First patient enrolled in June 2022 and Phase I trial ongoing in China ■ ICP-033 (DDR1, VEGF
Slide 17: Anticipated Milestones & Catalysts in Next Months
Anticipated Milestones & Catalysts in Next 12 Months ■ Orelabrutinib ■ Tafasitamab (CD19) ❑ r/r WM NDA approval ❑ NDA approval in Macau ❑ r/r MZL NDA approval ❑ Commence pilot use in GBA Liquid ❑ r/r MCL NDA approval in Singapore ❑ Submit NDA in Taiwan Cancer ❑ Complete 1L DLBCL-MCD registrational t
Slide 18: Financial Update
Financial Update Key Financials for 2022 Q1-Q3 Revenue R&D Costs (RMB mn) (RMB mn) Excluding Drug Sales 981 License-in upfront +30% 592 +2.3 times 776 475 475 400 442 226 42 366 175 30 400 366 175 2021.09.30 2022.09.30 2021.09.30 2022.09.30 2021.09.30 2022.09.30 2021.09.30 2022.09.30 Drug revenue R&
Slide 19: Science Drives Innovation for the Benefit of Patients
FORA BBM BAA Science Drives Innovation for the Benefit of Patients 18
InnoCare Pharma — Investor Presentation (January 2023) on 6ix